SPORE in Prostate Cancer

前列腺癌中的孢子

• 批准号: 10089059
• 负责人: Sarki A. Abdulkadir
• 金额: $ 165.68万
• 依托单位: NORTHWESTERN UNIVERSITY AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-08-18 至 2026-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10089059
• 关键词: Advocacy; Advocate; Aggressive course; American; Antibody Therapy; Antitumor Response; Basic Science; Bioinformatics; Biology; Biometry; Biopsy Specimen; Blood specimen; Cancer Etiology; Cancer Patient; Catchment Area; Chicago; Clinical; Clinical Sciences; Clinical Trials; Collaborations; Combined Modality Therapy; Comprehensive Cancer Center; Core Facility; DNA Damage; Development; Diagnosis; Disease; FDA approved; Family member; Focus Groups; Friends; Funding; Genetic Transcription; Health; Health system; Human; Immune system; Immunotherapy; Infrastructure; Innovative Therapy; Institution; Leadership; MHC Class I Genes; Malignant neoplasm of prostate; Measurable; Measures; Mediating; Metastatic Prostate Cancer; Myelogenous; National Cancer Institute; Oncogenic; PTEN gene; Pathologist; Pathway interactions; Patient Care; Patient-Focused Outcomes; Patients; Pharmacologic Substance; Phase I Clinical Trials; Phosphorylation; Pre-Clinical Model; Prostate specific antigen measurement; Quality of life; Regulation; Research; Research Personnel; Research Project Grants; Resistance; STING agonists; Scientist; Signal Transduction; Source; Talents; Testing; Therapeutic; Tissues; Translating; Translational Research; Translations; Treatment Efficacy; Tumor-infiltrating immune cells; Universities; Visceral; Work; Yang; anticancer research; base; bone; c-myc Genes; cancer genetics; career; castration resistant prostate cancer; cohort; design; experience; experimental study; humanized monoclonal antibodies; immune checkpoint blockade; improved; improved outcome; inhibitor/antagonist; innovation; investigator-initiated trial; meetings; member; men; mortality; mouse model; new technology; novel; novel strategies; novel therapeutics; patient population; preclinical study; programmed cell death protein 1; programs; prostate cancer model; recruit; safety study; success; targeted treatment; tumor; tumor microenvironment; tumor-immune system interactions

OVERALL: ABSTRACT This application is a request for renewal funding of the SPORE in Prostate Cancer P50 CA180995 at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University in collaboration with the University of Chicago Comprehensive Cancer Center and NorthShore University HealthSystem, an affiliate of the University of Chicago. The SPORE first received support from the National Cancer Institute in 2001; a renewal application was funded in 2009. In 2015, we were the recipients of a new SPORE and we are now requesting continued funding for this program. Our SPORE unites basic scientists, clinicians, pathologists, biostatisticians, bioinformaticists and advocates from our academic institutions, all of whom are dedicated to advancing translational prostate cancer research. In this application we propose three highly translational and innovative research projects that have both basic science and clinical science co-leadership: Project 1: Targeting the MYC Pathway in Prostate Cancer (Abdulkadir, Hussain); Project 2: Re-directing the sensitivity of metastatic castration-resistant prostate cancer to immunotherapy (Wu, Sosman, Morgans); Project 3: STING Activation to Overcome Resistance to Immune Checkpoint Blockade in PTEN-deficient Prostate Cancer (Patnaik, Gajewski, Stadler). Three core facilities support the proposed research projects: Administrative, Leadership and Advocacy (Abdulkadir, Hussain, Stadler); Biostatistics/Bioinformatics (Kocherginsky, Zhao) and Biospecimen (Yang). Internal and External Advisory Boards provide a source of scientific input to members of the SPORE team on a biannual and yearly basis, respectively. Our Advocacy Group are well established in the SPORE arena and make a valued contribution to our success. The SPORE includes Developmental Research and Career Enhancement Programs, both of which provide a source of innovation and new discoveries. All together, we anticipate that the results obtained from our research endeavors will have a significant impact on the health of patients diagnosed with prostate cancer.

总体：摘要 本申请是罗伯特大学前列腺癌P50 CA180995分生孢子的续期资助申请 西北大学H·卢里综合癌症中心与芝加哥大学合作 综合癌症中心和北岸大学医疗系统，该系统是加州大学的附属机构 芝加哥。该孢子在2001年首次得到国家癌症研究所的支持；续签申请 是在2009年资助的。2015年，我们收到了一个新的孢子，现在我们要求继续 为这个项目提供资金。我们的孢子联合了基础科学家、临床医生、病理学家、生物统计学家， 来自我们学术机构的生物信息学家和倡导者，他们都致力于推动 转化型前列腺癌研究。在本申请中，我们提出了三个高度可翻译和创新的方案 既有基础科学又有临床科学共同领导的研究项目：项目1：以多年来中心为目标 前列腺癌的途径(Abdulkadir，Hussain)；项目2：改变转移的敏感性 免疫疗法抵抗去势的前列腺癌(Wu，Sosman，Mgan)；项目3：STING激活以 克服对PTEN缺陷前列腺癌免疫检查点阻断的抵抗(Patnaik，Gajeski， 斯塔德勒)。三个核心设施支持拟议的研究项目：行政、领导和宣传 (Abdulkadir，Hussain，Stadler)；生物统计学/生物信息学(Kocherginsky，赵)和Biospecimen(杨)。 内部和外部咨询委员会为孢子团队成员提供科学投入的来源 分别以半年和一年为基准。我们的宣传小组在孢子舞台上有很好的地位 为我们的成功做出宝贵的贡献。孢子包括发展研究和职业生涯 增强计划，这两个计划都提供了创新和新发现的来源。总而言之，我们 预计从我们的研究工作中获得的结果将对健康产生重大影响 被诊断为前列腺癌的患者。